Article
Rheumatology
Nicolette T. Morris, Jenny Brook, Ami Ben-Artzi, William Martin, Tanaz A. Kermani, Lynette Avedikian-Tatosyan, George Karpouzas, Himakar Nagam, Geraldine Navarro, Soo Choi, Mihaela B. Taylor, David Elashoff, Gurjit S. Kaeley, Veena K. Ranganath
Summary: This study found that baseline and early changes in PDUS can predict later clinical response in RA patients treated with IV-TCZ for 24 weeks. Additionally, the use of PDUS 20/50/70 as a measurement is a novel metric of response.
CLINICAL RHEUMATOLOGY
(2021)
Article
Medicine, General & Internal
Soo Min Ahn, Ji Seon Oh, Hyun Mi Heo, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
Summary: This study retrospectively evaluated the incidence and risk factors of rheumatoid arthritis (RA) flares after switching from intravenous tocilizumab (TCZ-IV) to subcutaneous tocilizumab (TCZ-SC) in stable RA patients. The results showed that the dose of TCZ-IV per weight at switching and methotrexate (MTX) non-use were associated with the risk of RA flares after switching to TCZ-SC.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Rheumatology
Young-Eun Kim, Soo Min Ahn, Ji Seon Oh, Yong -Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong
Summary: The study aimed to determine the risks and clinical significance of tocilizumab (TCZ)-related neutropenia in patients with rheumatoid arthritis (RA). It was found that approximately 7% of RA patients treated with TCZ developed grade 3 neutropenia, but neutropenia was not a risk factor for infections during TCZ treatment.
Article
Rheumatology
Claire Rempenault, Cedric Lukas, Bernard Combe, Astrid Herrero, Isabelle Pane, Thierry Schaeverbeke, Daniel Wendling, Thao Pham, Jacques-Eric Gottenberg, Xavier Mariette, Jacques Morel
Summary: Patients with RA treated with TCZ have a higher risk of diverticulitis and GIP compared to those treated with RTX or ABA. These events occur earlier and have atypical clinical presentation in TCZ-treated patients.
Article
Pharmacology & Pharmacy
Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Diaz-Torne, Ana Milena Millan, Hye Sang Park, Adriana Lasa, Hector Corominas
Summary: Rheumatoid arthritis (RA) is a common autoimmune disease, and Tocilizumab (TCZ) is a commonly used treatment. This study found that the genetic variant rs4845625 in the IL6R gene is associated with the response to TCZ treatment, which may help predict the treatment effect for patients.
Article
Rheumatology
Shunsuke Mori, Yukitomo Urata, Tamami Yoshitama, Yukitaka Ueki
Summary: The study found that tofacitinib was more effective in inducing greater improvements in bDMARD-naive patients with active RA during the first 12 months of treatment compared to tocilizumab, but this difference was not observed in bDMARD-failure patients.
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Fredrik D. Johansson, Jamie E. Collins, Vincent Yau, Hongshu Guan, Seoyoung C. Kim, Elena Losina, David Sontag, Jacklyn Stratton, Huong Trinh, Jeffrey Greenberg, Daniel H. Solomon
Summary: The study developed a remission prediction model for TCZ monotherapy using machine learning algorithms and demonstrated good performance in real-world data. The conclusion showed that the remission prediction scores derived in RCTs discriminated patients in RWD as well as in RCTs, with further improvement in discrimination by retraining models in RWD.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Nanoscience & Nanotechnology
Dae Kyu Kim, Jun Young Park, Youn Joo Kang, Dongwoo Khang, Youn Joo Kang
Summary: This study successfully converted metformin into an anti-rheumatoid arthritis drug by encapsulating it in PLGA nanoparticles. The use of photothermal therapy further enhanced the anti-inflammatory effects of the nanodrug. The results demonstrated that this nanodrug combined with photothermal therapy effectively ameliorated inflammation in a spatiotemporal manner.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Multidisciplinary Sciences
Ashwin Kamath, Sahana D. Acharya, Rashmi R. Rao, Sheetal D. Ullal
Summary: The study compared the reporting of pancreatitis following TCZ use with other drugs using the FAERS database, and found a disproportionately high reporting of pancreatitis in patients receiving TCZ compared to other drugs. However, this marginally high reporting is not likely to be of immediate clinical concern.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Jun Won Park, Min Jung Kim, Hyoun-Ah Kim, Jin Hyun Kim, Eun Bong Lee, Kichul Shin
Summary: Tapering the dose of TCZ after achieving low disease activity in patients with rheumatoid arthritis increases the risk of losing low disease activity without significant safety benefits.
FRONTIERS IN MEDICINE
(2022)
Article
Health Care Sciences & Services
Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Diaz-Torne, Ana Milena Millan, Hye Sang Park, Adriana Lasa, Hector Corominas
Summary: A cohort study was conducted on 88 patients treated with Tocilizumab to investigate the association between single-nucleotide polymorphisms (SNPs) in the IL6R gene and adverse events. The results showed that certain SNPs were associated with dyslipidemia and hematological adverse events.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Medicine, General & Internal
Codrina Ancuta, Rodica Chirieac, Eugen Ancuta, Oana Tanculescu, Sorina Mihaela Solomon, Ana Maria Fatu, Adrian Doloca, Cristina Iordache
Summary: This study showed that tocilizumab can significantly improve gingival conditions in patients with periodontal disease in the short term, with notable impact on bleeding on probing and probing pocket depth. Additionally, significant correlations were found between periodontal status, disease activity, and serologic biomarkers.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Infectious Diseases
Yong Wang, Yongfeng Chen, Xiangdong Zhou
Summary: This study retrospectively evaluated the clinical characteristics and treatment response of TCZ therapy in 13 COVID-19 patients. The results showed that TCZ may have a certain therapeutic effect on severe COVID-19 patients with a risk of cytokine storm. However, further randomized controlled trials are needed to assess its efficacy and safety.
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
(2022)
Review
Rheumatology
Yvonne Tan, Maya H. Buch
Summary: This review summarises the key concepts of difficult to treat rheumatoid arthritis (D2T-RA) defined by the European Alliance of Associations for Rheumatology. D2T-RA is primarily characterized by the failure of at least two different mechanism of action drugs with evidence of active/progressive disease. The review suggests additional considerations in the definition of D2T-RA and the potential value of identifying D2T traits and intervening before the development of D2T-RA state.